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Introduction
Breast cancer is the second most frequent cancer in the 
world and by far, the most frequent cancer among women, 
with an estimation of 1.67 million new cases occurring in 
2012, according to the IARC (Ferlay et al., 2015). It is well 
known that breast cancer is a heterogeneous disease, that 
is classified in different molecular subtypes which show 
different features, response to treatment and outcome 
(Senkus et al., 2015). In the last two decades, enormous 
efforts have been made to characterize these subclasses 
at proteomic (Perou et al., 2000), genomic (Vogelstein 
and Kinzler, 2004) and epigenomic levels (Baylin and 
Ohm, 2006).
Nowadays, it is accepted that cancer harbors a genetic 
origin (Visvader, 2011). During breast tumorigenic 
process, genetic alterations known as driver mutations 
arise and progressively accumulate in tumoral cells 
deregulating multiple cell functions (Vogelstein et 
al., 2013). Despite the multiple existent cancer types, 
it has been proposed that cancer cells share similar 
characteristics. According to Hanahan and Weinberg 
(2011), these can be summarized in eight hallmarks, 
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among which invasion and metastasis is one of them. 
Cell migration and invasion represents the initial step 
of metastatic cascade: to disseminate and colonize 
distant organs, tumor cells need to degrade extracellular 
matrix (ECM) components and physically move to reach 
lymph and blood vessels. This is accomplished through 
the release of proteolytic enzymes known as Matrix 
Metalloproteinases (MMPs) (Sullu et al., 2011). 
It is important to remark that even though migration and 
invasion are necessary to the metastatic process, released 
tumor cells need to acquire modifications that allow them 
to adapt and survive. To adapt to their new environment, 
cancer cells can rely on epigenetic modifications, which 
are more flexible and highly dynamic in comparison to 
genetic modifications (Jones and Baylin, 2007). It has 
been shown that aberrant DNA methylation affects the 
function of genes involved in multiple processes including 
DNA repair and cell cycle regulation, angiogenesis and 
apoptosis (Moelans et al., 2011; Lindner et al., 2013).
Our previous studies have focused on the role that 
aberrant DNA methylation plays in breast carcinogenesis 
(Branham et al., 2016), and more specifically in metastasis 
development. For example, we previously identified a 
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CpG site in PAX6 gene that presented significant changes 
in the methylation status during the progression from 
primary breast tumor (PBT) to lymph node metastasis 
(LNM) (Urrutia et al., 2015). This change consisted of a 
methylation-to-unmethylation shift from PBT to LNM. 
We also established that this methylation had an impact 
on the expression of the PAX6 gene, which suggested that 
this epigenetic change induces a functional modification 
in metastatic lesions. 
PAX6 is a transcription factor, which has been 
highly-conserved across evolution. Its protein structure 
is characterized by the presence of two DNA binding 
domains, and it has been described as fundamental 
during early development of multiple organs, including 
eyes, central nervous system and pancreas (Shaham et 
al., 2012; Engelkamp et al., 1999). Thus, given its DNA 
binding properties, PAX6 can regulate the expression of 
other genes participating in multiple processes such as 
cell proliferation, differentiation and migration. Recent 
studies have inquired about its role in malignant tumors, 
and evidence suggest that PAX6 could function as an 
oncogene during breast tumorigenesis (Zong et al., 2011).
The present study aimed to investigate the impact 
of PAX6 promoter methylation over gene expression 
and how these changes impact breast carcinoma cells 
migration capacity. Our findings suggest that PAX6 is 
epigenetically regulated by promoter methylation and its 
expression contributes to cell migration of breast cancer 
cells by targeting Matrix Metalloproteinases 2 and 9.
Materials and Methods
Cell lines and cell culture
Breast cancer MCF-7 and MDA-MB-231 cells were 
kindly provided by Dr. Lanari from the IBYME institute, 
Buenos Aires, Argentina. MCF-7, MDA-MB-231 
and HeLa cell lines were cultured in DMEM growth 
medium (Gibco by Life technologies, Grand Island, 
NY, USA) supplemented with 10% FBS (Internegocios, 
BA, Argentina) 100U/ml penicillin and 100 µg/ml of 
streptomycin (Gibco by Life technologies, Grand Island, 
NY, USA). Cell lines were maintained at 37º C in humidified 
atmosphere containing 5% CO2. For demethylation 
assays, MDA-MB-231 cells were cultured in media 
containing 5 or 10µM of the demethylating agent 
5-Aza-2’-deoxycytydine (5-Aza) (Merck-Millipore, 
Billerica, MA, USA). The medium was changed once a 
day for 6 days with media containing fresh 5-Aza.
Methylation analysis by Methyl Specific- Multiplex 
Ligation Probe Amplification (MS-MLPA)
To assess the methylation status of 27 CpG sites 
located on 25 cancer related genes, including PAX6, 
DNA of MCF-7, MDA-MB-231 and HeLa cells was 
analyzed by MS-MLPA methodology using the kit 
ME002 (MRC Holland, Amsterdam, The Netherlands). 
Reactions were carried out following manufacturer’s 
instructions, including subtle modifications to avoid 
background signals. Fluorescent PCR products were 
separated by capillary electrophoresis in a Beckman 
CEQ8000 sequencer (Beckman Coulter Inc. Fullerton, 
CA, USA) and analyzed by the GeneMarker v1.75 
software (Softgenetics LLC, PA, USA). A CpG site was 
considered methylated when its value was higher than a 
pre-established cut-off of 15%, percentage which reflects 
the amount of methylated allele copies.
Quantitative Real Time PCR (qRT-PCR) 
Total RNA of cell lines was extracted using Trizol 
reagent (Ambion/Thermo Scientific, USA) following 
manufacturer’s recommendations. cDNA synthesis 
was carried out by reverse transcription of 500ng 
of total RNA using M-MLV reverse transcriptase 
(Promega, Madison, WI, USA) and Random Primers 
(Biodynamics, BA, Argentina) during 60 minutes 
at 37º C. Primers used included: PAX6 (forward) 
5′-CTTGGGAAATCCGAGACAGATT-3´; (reverse) 
5′-GCTAGCCAGGTTGCGAAGAAC-3´; MMP2: 
(forward) 5′-TCTCCGACATTGACCTTGGC-3´; (reverse) 
5′-CAGGGTGCTGGCTGAGTAGATC-3′; MMP9: 
(forward) 5′-TTGACAGCGACAAGAAGTGG-3′; 
(reverse) 5′-GCCATTCACGTTCGTCCTTAT-3′; GAPDH: 
(forward) 5′-TGGACCTGACCTGCCGTCTA-3′; 
(reverse) 5′-CCCTGTTGCTGTAGCCAAATT-3′. 
PCR reactions were performed on a Rotor Gene 6,000 
thermocycler (Corbett Research, USA) using the 
following conditions: 40 cycles of 30s at 95º C, 30s at 
56º C and 30s at 72º C. The expression of genes of interest 
was relativized considering GAPDH as reference gene, 
using the ∆CT method.
Plasmids and transfections
For functional analysis, cells were transfected with a 
pcDNA-GFP plasmid alone or co-transfected with GFP 
and pMxs-PAX6 plasmid. pMxs-PAX6 plasmid was a 
gift from Kevin Eggan (Addgene plasmid #32932). For 
interference of PAX6, cells were co-transfected with 
GFP plasmid and scramble siRNA A or siRNA PAX6 
(#sc-37007 and sc-36195, Santa Cruz Biotechnology, 
Dallas, TX, USA). Transfections were carried out using 
Lipofectamine 2000 (Invitrogen, Van Allen Way Carlsbad, 
CA, USA) according to manufacturer’s instructions.
Migration assays
MDA-MB-231 and HeLa cell lines were cultured 
and transfected as previously described. Twenty-four 
hours after transfection or 5-Aza treatment, cells were 
incubated overnight in serum-reduced medium containing 
0.5% FBS. Cell surface was then scratched using a 200 
µL pipet tip and washed with PBS to remove detached 
cells and debris. Cells were photographed every 24 hours 
using a TE300 Eclipse microscope equipment (Nikon, 
Tokyo, Japan). Images obtained were then processed 
using Image J software. Reduction of the scratched area 
was measured and expressed as migration percentage 
according the formula: ((Areat0-Areat1)/Areat0) x100, 
where T0 represents area at initial time point and T1 
represents area at time point of interest. 
Bioinformatic assays
MMP2 and MMP9 sequences were analyzed by means 
of bioinformatic tools to detect promoters, evolutionary 
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statistically significant.
Results
PAX6 is methylated in MCF-7 and MDA-MB-231 breast 
cancer cell lines
To determine the impact of PAX6 promoter methylation 
over its expression, we analyzed by MS-MLPA the 
methylation status of a CpG site located in PAX6 
gene promoter, in breast cancer cell lines MCF-7 and 
MDA-MB-231. Previous data from our group has shown 
that the cervix cell line HeLa does not present methylation 
at the studied CpG site, therefore we included them in 
our analysis to further evaluate the relation of lack of 
methylation at promoter and PAX6 gene expression. 
MS-MLPA assays showed that MCF-7 and MDA-MB-231 
cell lines present high levels of methylation in the 
PAX6 CpG site assessed (90% and 100% of the allele 
copies, respectively), while HeLa cells did not show 
methylation at this site (Figure 1A). Since promoter 
methylation is an important mechanism implicated in 
gene expression regulation during tumorigenesis, we 
assessed the expression of PAX6 mRNA by qRT-PCR 
on MCF-7 and MDA-MB-231 breast cancer cell lines 
and HeLa cell line. We found that PAX6 expression on 
conserved regions and potential binding sites for PAX6 
protein. A two species non-coding alignment was 
performed using mVISTA (http://genome.lbl.gov/vista/) 
with a window of 50 base pairs and 70% identity. 
The alignment was performed among human MMP2 
(Accession #NG_008989.1) and MMP9 (Accession # 
NG_011468.1), and their respective mouse orthologues 
sequences: Mmp2 (Accession #NM_0088610) and 
Mmp9 (Accession #NM_013599). Detection of MMP2 
and MMP9 promoter regions and first exon was carried 
out with First EF prediction software (http://rulai.cshl.
org/tools/FirstEF/) using default parameters. Potential 
PAX6 paired domain binding sites were identified using 
the Transfac based rVISTA program (http://genome.lbl.
gov/vista/) and the JASPAR CORE database with matrices 
M00979 and MA0069. Nucleotides ranging from -3,000 
to +500 to the TSS of MMP2 and MMP9 sequences were 
tested, using an 80% matrix similarity cutoff.
Statistical analysis 
Statistical analysis was performed using GraphPad 
Prism 5.03 Software. Results are expressed as the mean ± 
SD of three independent experiments. Statistical analysis 
of mean differences between two groups was performed 
by Student’s t-test. P values <0.05 were considered as 
Figure 1. PAX6 Methylation Status and Expression in Breast Cancer Cell Lines. A, The PAX6 gene methylation status 
on cancer cell lines is shown in the table. Red boxes represent methylated status; green boxes represent unmethylated 
status. Methylation at the assessed CpG site is expressed as a percentage, representing the amount of methylated allele 
copies in the sample; B, PAX6 mRNA expression relative to GAPDH gene for MCF-7, MDA-MB-231 and HeLa cell 
lines is represented in the histogram; C, The effect of 5-Aza treatment on PAX6 methylation was tested at increasing 
concentrations. *P <0.05; D, The effect of 5-Aza treatment on PAX6 mRNA expression was assayed by qRT-PCR. 
Histogram shows PAX6 expression before and after (left and right respectively) treatment at 5uM. *P <0.02 
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MCF-7 and MDA-MB-231 cells do not differ significantly 
between both breast cancer cell lines. This observation 
suggested that high methylation on PAX6 promoter have 
similar effect over PAX6 mRNA expression level (Figure 
1B), while lack of methylation correlates with higher 
expression of PAX6, as observed in HeLa cell line.
5-Aza-2’-deoxycytydine treatment reverses methylation 
and increases PAX6 expression
Since PAX6 promoter was methylated on both 
breast cancer cell lines, and methylation is associated 
with gene repression, we asked whether demethylation 
of the PAX6 promoter could restore PAX6 gene 
expression. To answer this question, we chose to work 
with the MDA-MB-231 cell line, which presented the 
highest methylation level of PAX6. MDA-MB-231 
cells were treated with the demethylating agent 5-Aza 
at concentrations of 5 and 10 µM and subjected to 
methylation assays by MS-MLPA. We observed that 
5-Aza treatment reduced PAX6 methylation significantly, 
from 100% to 78% (± 7,3%) and 75,5% (± 3,5%) in the 
5 and 10 µM groups respectively (P= 0.01) (Figure. 
1C). After confirming that treatment with 5-Aza reduces 
PAX6 methylation, we evaluated whether treatment with 
5 µM of 5-Aza induced changes in PAX6 expression in 
MDA-MB-231 cells. We observed by qRT-PCR, that 
PAX6 expression in the 5-Aza treated cells was increased 
when compared with control MDA-MB-231 cell line 
(P< 0.02) (Figure 1D). 
Our results suggest that methylation at this specific 
CpG site located on PAX6 promoter downregulates 
i ts  expression,  and t reatment  with the drug 
5-Aza-2’-deoxycytydine increases PAX6 expression 
through promoter demethylation.
PAX6 expression regulates MDA-MB-231 cell migration 
ability
Since cell migration is one of the initial steps of the 
metastatic cascade and we previously reported that PAX6 
is unmethylated and expressed in cells from metastatic 
breast cancer lesions, we asked if PAX6 expression could 
be contributing to the migration potential of breast cancer 
cells. To answer this, we transfected MDA-MB-231 cells 
with a GFP encoding plasmid (GFP) or co-transfected 
with GFP plus PAX6 encoding vector (GFP/PAX6). Next, 
we performed wound healing assay. As shown in Figure. 
Figure. 2 Effect of Ectopic PAX6 Overexpression and PAX6 Inhibition by siRNA Transfection on Cancer Cell 
Migration. A, Representative photographs of migration assays performed on MDA-MB-231 cells transfected either 
with GFP alone or GFP/PAX6 (left and right respectively); B, Bar graph representation of wound healing assays. Cell 
migration is expressed as percentage of wound closure. Columns represent the mean ± SD of at least 3 independent 
experiments. *P <0.05; C, Histogram representation of wound healing assays performed on HeLa cell line. Cell 
migration is expressed as percentage of wound closure. Columns represent the mean ± SD of at least 2 independent 
experiments. *P <0.05
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2A and B, PAX6 overexpression increased migration in 
GFP/PAX6 transfected cells as compared with the control 
GFP cells at 48 hs (76% ± 7,8% vs. 63% ± 5%, P= 0.04). 
From this observation, we hypothesized that PAX6 
expression could be promoting cell migration in these 
breast carcinoma cells. To test our hypothesis, we decided 
to evaluate migration on HeLa cells, on which we 
showed that do not present PAX6 promoter methylation 
and express PAX6 (Figure 1 A, B). We performed 
co-transfection with a GFP encoding plasmid and scramble 
siRNA (GFP/siRNA A) or with GFP and siRNA PAX6 
(GFP/siRNA PAX6). Cells were then subjected to wound 
healing migration assay. As shown in Figure 2C, we found 
that HeLa cells migration ability was significantly reduced 
in the siRNA PAX6 transfected cells when compared with 
the siRNA A control cells (33,8% vs. 18,6%, P= 0.03).
Taken together, the results obtained by migration 
assays allowed us to conclude that PAX6 plays a role in 
cell motility, promoting cell migration.
PAX6’s role in MDA-MB-231 cell migration is 
epigenetically regulated
Given that PAX6 expression is regulated by DNA 
methylation and since ectopic expression and interference 
assays showed that PAX6 contributes to breast cancer cell 
migration potential, the role of PAX6 methylation in cell 
migration was investigated. We treated MDA-MB-231 
cells with the demethylating agent 5-Aza and then 
performed transfection with GFP or GFP/siRNA PAX6 
followed by migration assays. As shown in Figure 3B 
first and second bars, 5-Aza treatment reduced migration 
when compared to control cells at 72hs (65,8% ± 3,2% 
vs. 100% respectively, P< 0.01), as expected from an 
antineoplastic drug. 
Given that 5-Aza has unspecific effect over global 
DNA methylation, to assess the individual contribution 
of PAX6 demethylation to migration we compared 5-Aza 
MDA-MB-231 treated cells after transfection with GFP 
and GFP/siRNA PAX6. PAX6 siRNA inhibition after 
5-Aza treatment significantly reduced cell migration 
when compared with 5-Aza + GFP alone transfected cells 
(32,5% ± 6,2% vs. 49% ± 3,6%, P= 0.034) (Figure 3b, 
third and fourth bars). 
These data indicate that PAX6’s contribution to 
cell migration is epigenetically regulated, since the 
methylation of its promoter decreases the migration ability 
of breast cancer cells.
MMP2 and MMP9 genes present PAX6 specific binding 
sites at promoter regions
Since cell migration is associated with tissue invasion 
as the initial steps of the metastatic cascade and given 
that PAX6 is a transcription factor with well-known DNA 
binding properties, we hypothesized that PAX6 could be 
Figure 3. Effect of PAX6 Demethylation and Inhibition by siRNA on Cell Migration Capacity. A, Representative 
photographs of migration assays performed on MDA-MB-231 cells after treatment with 5-Aza at 5µM and transfection 
with either GFP or GFP/siRNA PAX6; B, Histogram representation of wound healing assays performed on MDA-
MB-231 cell line. Cell migration is expressed as percentage of wound closure. Columns represent the mean ± SD of 
at least 3 independent experiments. **P< 0.01 and *P< 0.05. 
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contributing to the initial events of the metastatic process 
by regulation of other genes. To test this, we analyzed 
the DNA sequences of Matrix Metalloproteinases 2 and 
9 genes, which encode two important enzymes involved 
in cell migration and invasion of surrounding tissues, to 
identify the presence of potential binding sites for PAX6 
protein. 
First, we sought for the presence of promoter regions 
by using the FirstEF software. We identified the presence 
of two promoters in the 5ʼ regulatory region of MMP2 
gene (-2,075 bp to -1506 bp and -440 bp to +229 bp) and 
one promoter within the MMP9 gene (-793 bp to -224 bp). 
Given that regulatory elements often reside in evolutionary 
conserved regions (ECRs), we used the mVISTA software 
to perform non-coding alignment among MMP2 and 
MMP9 sequences and their corresponding murine 
orthologues Mmp2 and Mmp9. Within the MMP2 gene, 
two ECRs were identified, A: 184 bp (from -312 bp to -128 
bp) and B: 304 bp (from -89 bp to +215 bp). Analysis on 
the MMP9 gene revealed the presence of an ECR ranging 
from -6 bp to +180 bp of the major transcription start 
site (TSS). Next, we analyzed the MMP2 and MMP9 5ʼ 
non-coding DNA sequences searching for PAX6 paired 
domain binding sites, using mVISTA program and the 
JASPAR CORE matrices. Using these tools, we identified 
4 putative binding sites in the MMP2 regulatory DNA and 
focused on two that reside in the ECRs of the distal, as 
shown in Figure 4A. Within the MMP9 regulatory DNA, 
we found two putative binding sites of which we focused 
in the first one, located 40 bp downstream of the TSS, 
within the ECR (Figure 4B). 
Based on these findings, we hypothesized that PAX6 
could be contributing to initial steps of metastatic cascade 
on breast cancer cells by regulating the expression of 
MMP2 and MMP9 genes, possibly binding to their 
promoter regions.
 
PAX6 overexpression increases MMP2 and MMP9 
expression
Based in the in-silico assays, we decided to test 
our previous hypothesis whether MMP2 and MMP9 
expression is regulated by PAX6, by modulating the 
Figure 4. A Structure of the MMP2 gene. Promoter regions are shown as white boxes. At the distal promoter, 
evolutionary conserved regions (ECR) A and B are shown as blue boxes. Two potential binding sites for PAX6 protein 
(BS1 and 2) were detected inside the ECRs A and B using JASPAR database (orange stripes). PAX6 binding sites 
sequences are shown above. B Structure of the MMP9 gene. An ECR (blue box) is shown flanking promoter region 
(white box). PAX6 binding site (orange stripe) is located at +40 bp of TSS. PAX6 binding site sequence is shown. C 
Graph bar representation of MMP2 mRNA expression relative to GAPDH for MDA-MB-231 cells transfected either 
with GFP or GFP/PAX6. **P< 0.01. D Graph bar representation of MMP9 mRNA expression relative to GAPDH for 
MDA-MB-231 cells transfected either with GFP or GFP/PAX6. P= 0.06.
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expression of PAX6 on MDA-MB-231 cell line. To do this, 
we evaluated by qRT-PCR the expression of both MMPs 
on MDA-MB-231 cells transfected with GFP or GFP/
PAX6. We found that PAX6 overexpression on the GFP/
PAX6 transfected cells increased both MMPs transcripts 
when compared to the MDA-MB-231 GFP cells. The 
increase in expression was significant for MMP2 (P <0.01, 
Figure 4C). MMP9 also increased mRNA expression, 
although it did not reach statistical significance (P= 0.06, 
Figure 4D). 
Taken together, the changes observed after modulation 
of PAX6 expression evidenced the existence of a positive 
regulation of PAX6 over the MMP2 and MMP9 genes, by 
increasing their expression. 
Discussion
In the last years, many authors have contributed to 
understand the role of aberrant DNA methylation during 
tumorigenesis, demonstrating its involvement in human 
malignancies including breast and others (Esteller, 2005). 
Despite its importance, a limited number of studies have 
assessed the specific contribution of this epigenetic 
mark to the molecular events that lead to metastasis 
establishment. The present study demonstrates that 
PAX6 expression is epigenetically regulated by promoter 
methylation and that PAX6 over-expression enhances 
cell migration and expression of MMP2 and MMP9, two 
well-known proteases involved in cancer cells migration 
and invasion during metastasis development. Furthermore, 
we also found that PAX6 promoter methylation negatively 
impacts on cell migration, supporting the notion that PAX6 
has a pro-oncogenic role on mammary carcinogenesis. 
PAX6 has been demonstrated to be involved in 
development of eye, central nervous system and pancreas 
(Shaham et al., 2012; Engelkamp et al., 1999). Besides 
its function during development, PAX6 has also been 
reported to play different roles in malignant tumors 
(Shyr et al., 2010; Salem et al., 2000). However, there is 
a controversy about PAX6 and its specific role in human 
cancers. For instance, in neoplasms of the CNS such as 
gliomas and glioblastomas, it has been postulated as a 
tumor suppressor gene, whose down-regulation enhances 
cell invasiveness (Mayes et al., 2006; Cheng et al., 2014). 
In other cancer types, an opposite function is proposed: 
In lung cancer cell lines PAX6 inhibition reduces cell 
proliferation (Zhao et al., 2014), while in retinoblastoma, 
overexpression of PAX6 has been reported (Wang et al., 
2013). Globally, these findings support the notion that 
PAX6 role during tumorigenesis could be dual and tissue 
specific and influenced by multiple variables including 
the tissue microenvironment and other epigenetic factors.
In breast cancer, Zong et al., (2011) suggested 
that PAX6 promotes cancer cell proliferation and 
tumorigenesis. However, the role that PAX6 plays during 
metastatic cascade as well as the underlying molecular 
mechanisms, remain unknown. Our group has reported 
that the CpG site of PAX6 evaluated in this study 
changed its methylation status during progression from 
PBT to LNM. We also established that this mark has 
an impact on the expression of PAX6 gene in primary 
tumor and LNM, suggesting that this change induces a 
functional modification in the metastasis (Urrutia et al., 
2015). We tested this hypothesis by evaluating migration 
after modulation of PAX6 expression, finding that over 
expression of PAX6 on MDA-MB-231 cell line increases 
migration. To confirm the participation of PAX6 expression 
on cell migration, we evaluated migration on HeLa cell 
line after cell transfection with an siRNA for PAX6. Our 
results showed that interfering PAX6 expression reduced 
migration of HeLa cells. More importantly, we confirmed 
that PAX6 promoter methylation reduces cell migration by 
performing migration assays on MDA-MB-231 cells after 
5-Aza treatment and siRNA/PAX6 transfection. Our results 
obtained by MS-MLPA and qPCR indicate that 5-Aza 
treatment can reduce PAX6 methylation and increase its 
expression on MDA-MB-231 cells. Subsequent inhibition 
of PAX6 after 5-Aza treatment showed greater reduction 
of migration when compared with control and 5-Aza alone 
treated cells. This observation reveals the importance of 
methylation in cell migration and supports our previous 
theory that cells without PAX6 methylation have greater 
chances of leaving primary tumor and establishing on 
distant organs like lymph nodes.
In addition, the present study demonstrates that mRNA 
levels of MMP2 and MMP9 are increased in PAX6 
overexpressed cells. MMP2 and MMP9 are two proteases 
secreted by tumor cells, that degrade components of 
basal membrane and extracellular matrix, thus linking 
cancer cells with invasion and metastasis. Our results 
here described are in line with those informed by Li et al., 
(2014) who found that PAX6 promotes invasion in colon 
cancer by upregulation of both MMPs. In a similar manner, 
Meng et al., (2015) reported that PAX6 down-regulation 
by miRNA-335 reduces cell invasion in MCF-7 cells. 
Besides our functional assays, our bioinformatic assays 
provide evidence of the existence of specific binding sites 
for PAX6 in the regulatory regions of both MMPs genes. 
Mayes et al., (2006) previously reported the presence of 
a 245 bp PAX6 responsive region ranging from -177 to 
+68 bp of the MMP2 TSS, suggesting the existence of a 
PAX6-specific binding site. This PAX6 responsive region 
overlaps with the ECR B region and the second PAX6 
binding site we described in the MMP2 gene promoter, 
supporting the hypothesis that PAX6 binding to this 
region is the mechanism involved in regulation of MMP2 
expression. In a similar way, Sivak et al., (2004) previously 
confirmed the activation of MMP9 promoter by PAX6. 
However, the binding site described in this study is not 
the same as previously reported by Sivak. Therefore, the 
functionality of the PAX6 binding site we describe in this 
report must be further confirmed.
Overall data from this study supports the pro-migratory 
role of PAX6 in breast carcinoma and delineate one 
of its possible mechanisms: we postulate PAX6 as an 
epigenetically regulable transcription factor that promotes 
migration and increases expression of the pro-metastatic 
proteins MMP2 and MMP9. 
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